The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines

Investigational New Drugs

Volumn 33, Issue 4, 2015, Pages 801-809

  Tonissi, Federica ^a   Lattanzio, Laura ^a   Merlano, Marco C ^a   Infante, Lucia ^a   Lo Nigro, Cristiana ^a   Garrone, Ornella ^a  

^a S Croce e Carle City Hospital   (Italy)

Author keywords

Bevacizumab; Metastatic breast cancer; Nab paclitaxel; Paclitaxel; SPARC; VEGF

Indexed keywords

BETA ACTIN; BEVACIZUMAB; MULTIDRUG RESISTANCE PROTEIN 1; OSTEONECTIN; PACLITAXEL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; SPARC PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MONOTHERAPY; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; METABOLISM; TUMOR CELL LINE;

ALBUMINS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BEVACIZUMAB; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; OSTEONECTIN; PACLITAXEL; RECEPTORS, ESTROGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943357724     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0249-z     Document Type: Article

References (29)

1. Cardoso F, Costa A, Norton L, Senkus E, Apro M, André F, Barrio CH, Bergh J, Biganzoli L, Blackwel KL (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871-1888. doi:10.1093/annonc/mdu385
2. Cardoso F, Costa A, Norton L, Senkus E, Apro M, André F, Barrio CH, Bergh J, Biganzoli L, Blackwel KL (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23:489-502. doi:10.1016/j.breast.2014.08.009
3. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685
4. Kloover JS, Den Bakker MA, Gelderblom H, van Meerbeeck JP (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90:304-305. doi:10.1038/sj.bjc.6601303
5. Li CJ, Li YZ, Pinto AV, Pardee AB (1999) Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci U S A 96:13369-13374. doi:10.1073/pnas.96.23.13369
6. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068. doi:10.1200/JCO.2004.08.048
7. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagy GN, Ellerhort JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin CancerRes 8:1038-1044
8. Schnitzer JE, Oh P (1992) Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol 263:H1872-H1879
9. Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, Ran S (2008) Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor a therapy. Neoplasia 10:613-623
10. Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, Ran S (2011) Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 13:327-338
11. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14:4200-4205. doi:10.1158/1078-0432.CCR-07-4592
12. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676. doi:10.1056/NEJMoa072113
13. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J (2005) J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803. doi:10.1200/JCO.2005.04.937
14. Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611-3619. doi:10.1200/JCO.2008.18.5397
15. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, et al (2014) A randomized phase III trial comparing nanoparticle-based (nab) paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer GBG 69-GeparSepto. SABCS Abs S2-07
16. Rugo HS, Barry, Aspitia AM, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP (2012) CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 30 (suppl; abstr CRA1002)
17. Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M, Lo Nigro C (2013) Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs 31:1107-1114. doi:10.1007/s10637-013-0005-1
18. Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M (2008) The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int 102:622-627. doi:10.1111/j.1464-410X.2008.07706.x
19. Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxanes. Expert Opin Pharmacother 7:1041-1053. doi:10.1517/14656566.7.8.1041
20. Piccart M (2009) nab™-paclitaxel: a targeted chemotherapy to improve outcomes in metastatic. Breast Cancer APJOH 1:5-12
21. Di Costanzo F, Gasperoni S, Rotella V, Di Costanzo F (2009) Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer. Oncol Targets Ther 2:179-188
22. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 1:4136-4143. doi:10.1158/1078-0432.CCR-04-2291
23. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324. doi:10.1158/1078-0432.CCR-05-1634
24. Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE (2014) Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer. Mol Cancer Ther 13:1032-1043. doi:10.1158/1535-7163.MCT-13-0361
25. Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA (2014) SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 63:974-83. doi:10.1136/gutjnl-2013-305559
26. Al-Batran SE, Geissler M, Seufferlein T, Oettle H (2014) Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. Oncol Res Treat 37:128-34. doi: 10.1159/000358890
27. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Nielsen KV, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS (2013) Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 19:1281-1289. doi:10.1158/1078-0432.CCR-12-3029
28. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, Horwitz SB (2005) Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 65:2854-2860. doi:10.1158/0008-5472.CAN-04-4391
29. Suzuki S, Sakurai K, Nagashima S, Hara Y, Amano S, Enomoto K, Makishima M (2014) Efficacy of bevacizumab in combination with Paclitaxel for metastatic breast cancer. Gan To Kagaku Ryoho 41:1289-1291